Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. - Wikidata - wikimedia - TriplyDB

Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.

Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.

http://www.wikidata.org/entity/Q33408261

about

Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Unusual Patterns of Thoracic Metastasis of Urinary Bladder Carcinoma.Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review.A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma.Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis

P2860

Q33431220-8BF9233D-4547-4395-9B07-F05589669F7A Q33743860-644C7300-40B9-4581-AFE3-59FDCDEB0837 Q37665453-F1B88D10-A440-4CF7-B037-986889A6CE4A Q38312045-6631C6E0-41CB-4950-BC60-7B14566DD8AF Q38669606-5645A5BA-E03C-44D8-9A95-ED618EAEB033 Q47103525-47AFBE24-4348-402C-BA59-E508E5B72CB8 Q57073547-7CC2F3D0-DDD9-4F16-ABA3-3EA05F6B552A

P2860

Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.

http://www.wikidata.org/entity/Q33408261

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@ast

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@en

type

label

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@ast

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@en

prefLabel

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@ast

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@en

P1433

Q33408261-409BB2E9-0B27-4C48-B46F-FDC587B49883

P1476

Q33408261-CA7A091F-36C0-4BFB-A462-C02549789F27

P2093

Q33408261-35F1DC4E-5F1D-4EA2-9E50-D5725386B3F8

Q33408261-5024E56E-FC66-4FA6-9995-73DAD8770AE0

Q33408261-77231213-94B0-4DAB-B01C-FCF8B5A795C6

Q33408261-86D6DE93-2B34-4CC5-8DA0-973FE9502BE7

Q33408261-8ACFA3F3-EA4F-41EF-979C-59B158AA48F9

Q33408261-A6FC0C03-304E-407E-965D-DEA02E69010B

P2860

Q33408261-07F59383-ED52-4832-ADDA-1ABA5170932B

Q33408261-23E3F626-7600-46C5-BA46-14A3D78A451C

Q33408261-251E1F0A-FC66-49EC-B8A2-97DFC28D2D88

Q33408261-2A0BF3DD-A254-4FFE-846F-FA11E81DCD4D

Q33408261-35F1F1C0-4166-4B5E-97D4-30993C9CD5D5

Q33408261-374694D5-56E9-4872-90F6-361D1814C99E

Q33408261-37574F94-164A-4FE4-A607-16E4396042A4

Q33408261-47570944-8614-43E3-9092-E1F386D27BE5

Q33408261-4FDA42A8-0F2F-4954-BECD-87D258A1531F

Q33408261-7EBCD8CA-B699-4E8C-AF3F-C64EF291B437

P2888

Q33408261-180809B5-AB35-422F-AD08-C3A550234A51

P304

Q33408261-A0F9F8A2-97BA-4521-B1F4-5CDEDD820C65

P31

Q33408261-E5BE569D-21FB-40D9-B983-2DA9576999D3

P356

Q33408261-CFCEA2C5-3A13-4E53-9D63-D0D246AFAC3A

P433

Q33408261-079D8991-951C-46EE-904C-45315DCE0539

P478

Q33408261-DF8F1AAC-B012-483D-AA86-BAB4CE4A0F8D

P50

Q33408261-590C0409-0F38-45ED-B6FB-6F7410C1E183

Q33408261-61C7F564-4AB2-4DAB-A04C-E4D0F3AE1A43

Q33408261-712B509A-5E38-4337-8F2C-689D681CB91E

Q33408261-C4665784-C330-4752-9E81-0F956A8D8FAA

P577

Q33408261-A68B897D-F365-497C-AAE9-967010111787

P5875

Q33408261-6D60ACCD-8458-4BF7-B52F-A806D49AA33A

P698

Q33408261-9A05BBDC-67BF-4D6F-B155-F3E404A31E20

P356

S10147-013-0574-1

P1433

International Journal of Clinical Oncology

P1476

Gemcitabine and docetaxel, an ...... tasis of urothelial carcinoma.

@en

P2093

Keiichi Tozawa

http://www.w3.org/2001/XMLSchema#string

Kenjiro Kohri

http://www.w3.org/2001/XMLSchema#string

Noriyasu Kawai

http://www.w3.org/2001/XMLSchema#string

Ryosuke Ando

http://www.w3.org/2001/XMLSchema#string

Toshiki Etani

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Hashimoto

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.

Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.

Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.

Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.

Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.

Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothel

P2888

s10147-013-0574-1

P304

516-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-013-0574-1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Takehiko Okamura

P577

2013-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237093073

http://www.w3.org/2001/XMLSchema#string

P698

23749066

http://www.w3.org/2001/XMLSchema#string